Comparative effectiveness of cardiovascular outcomes in new users of SGLT-2 inhibitors - CVD-REAL

Study identifier:D1690R00015

ClinicalTrials.gov identifier:NCT02993614

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Characteristics and cardiovascular and mortality outcomes in patients with type 2 diabetes mellitus initiating treatment with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) and other glucose lowering drugs

Medical condition

Diabetes mellitus type 2

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

99999

Study type

Observational

Age

N/A

Date

Study Start Date: 30 Nov 2017
Primary Completion Date: 17 Dec 2020
Study Completion Date: 17 Dec 2020

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria